Seta Clinic Group
Seta Clinic Group ("SCG") was established as the first specialized clinic of
Immuno-Cell Therapy for cancer patients, in March, 1999. SCG has continued to challenge
expansion and development of Immuno-Cell Therapy with its philosophy,"Through the
medical practice of Immuno-Cell Therapy, we create and advance a multidisciplinary treatment
of cancer which is harmless to the mind and body in order to improve Quality Of Life for
patients and their families." Over the past decade, its accumulated number of patients
has exceeded more than 10,000. SCG has also performed collaborative clinical studies for
further improvement in efficacy of Immuno-Cell Therapy with university hospitals, including
Tokyo University Hospital.
Further information at "About Seta Clinic Group"
Immuno-Cell Therapy
Immuno-Cell Therapy is a theoretically proved option of immunotherapy that anti-cancer
immune resistance of the patient is augmented. This therapy entails only minimal adverse
effects, since patient's own materials (cells and blood plasma for culture) are used
exclusively and is basically free from hazards such as undesirable immune reactions and
infections caused by viral contaminations.
Immuno-Cell Therapy is classified into two types: (1)autologous activated lymphocyte therapy
(formerly called adoptive immunotherapy) and (2)dendritiuc cell vaccine therapy, in which
dendritic cells (a type of cells in the immune system, specialized in antigen-specific
stimulation of lymphocytes) are utilized.
Further information at "About Immuno-Cell
Therapy"
Guidance to Treatment Procedure
Immuno-Cell Therapy is generally conducted by following process; (1)immune cells are taken
out from the body of a cancer patient, (2) immune cells are propagated and activated
strongly by reagents outside of the body, and then (3) immune cells are reinfused back to
the body of the original patient.
Further information at "Guidance to Treatment
Procedure"
Seta Clinic Tokyo
3F New Surugadai Bld.2-1-45 Kanda-Surugadai, Chiyoda-ku Tokyo, 101-0062 JAPAN
